📝 What This Document Is 📰

This filing is an 8-K, which is a mandatory SEC filing used to quickly announce important, material events about a company. In this case, Monopar Therapeutics (MNPR) is using it to announce that they are presenting critical Phase 3 clinical trial data for their drug, ALXN1840, at the American Academy of Neurology (AAN) Annual Meeting in April 2026.

👉 What readers should expect: This is not a financial filing, but a scientific progress update. It means the company is taking a major step forward in drug development, building toward a potential regulatory filing with the FDA.

🐶 What Monopar Therapeutics Does 🧬

In simple terms, Monopar Therapeutics is a clinical-stage biopharmaceutical company. This means they are a drug developer that has compounds in different stages of testing, aiming to bring new treatments for serious, unmet medical needs to patients.

👉 Their core focus is developing innovative treatments, particularly for rare genetic disorders like Wilson disease, and advanced cancers. They are working to solve complex health problems that current medicines don't address well.

🧠 Understanding Wilson Disease 🦠

Wilson disease is a severe and rare genetic disorder. It is caused by mutations in the ATP7B gene, which messes up the body’s natural ability to excrete excess copper. This leads to toxic build-up of copper in organs like the liver and the brain.

👉 The accumulation of copper is dangerous, potentially leading to progressive and serious health outcomes if left untreated. Because the damage can affect the central nervous system, it presents a major challenge for doctors to treat effectively.

✨ The Treatment: ALXN1840 💊

The company's key drug is ALXN1840 (tiomolibdate choline, TMC). This is described as a novel, first-in-class Albumin Tripartite Complex (ATC) activator. Think of it as a specialized compound that targets copper deposits in the body.

👉 Its mechanism of action is key: ALXN1840 rapidly mobilizes and tightly sequesters excess copper into ATCs. This process reduces copper’s damaging "redox reactivity" and helps block copper from crossing the blood–brain barrier, directly addressing the core problem of Wilson disease.

📊 Phase 3 Study Results for ALXN1840 📈

The core of this filing is the presentation of data from the randomized controlled Phase 3 FoCus trial. This trial compared the safety and effectiveness of ALXN1840 against the current standard of care (SoC) in patients with neurologic Wilson disease.

👉 The headline finding is that ALXN1840 showed a greater neurological benefit and a lower likelihood of neurologic worsening compared to the standard treatments. This was observed through Week 48 and sustained over many years.

Key Clinical Metrics Explained

• Worsening Rate: Clinically meaningful neurologic worsening was seen in 25% of patients on standard of care, compared to only 9% of patients on ALXN1840. (p=0.038).
  • Why it matters: This shows that ALXN1840 is significantly better at preventing the disease from getting worse, which is a major measure of success for a neurological disorder.
• Improvement Rate: Clinically meaningful neurologic improvement was seen in 45% of ALXN1840-treated patients versus 32% on standard of care.
  • Why it matters: A higher rate of improvement indicates that the drug is actively helping patients get better, not just preventing decline.
• Scale of Improvement (CGI Scores): The improvement in the Clinical Global Impression of Symptom (CGI-S) from baseline to Week 48 was 61% with ALXN1840 versus 17% with standard of care. (p=0.008). A similar strong improvement was noted for the CGI-I (47% vs 19%; p=0.003).
  • Why it matters: The CGI scores are objective measures of overall neurological function. The large difference here provides strong, quantifiable evidence that the drug works far better than existing options.

🛡️ Safety and Durability Data 🕰️

The data also provided strong evidence regarding the drug's safety and its ability to maintain benefits over time, which are critical factors for any new medication.

👉 The drug demonstrated a well-characterized and favorable safety profile. Over the study period, drug-related serious adverse events (SAEs) were limited to 4.9% of patients, with neurologic SAEs accounting for less than 1%. 👉 Furthermore, the neurologic benefit was durable, continuing to increase and being sustained over approximately 3 years of follow-up, even for long-term patients.

🎯 Looking Ahead: Next Steps for ALXN1840 🚀

The positive results are driving the company's development timeline. Based on these findings, Monopar Therapeutics plans to continue advancing ALXN1840 toward a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in mid-2026.

👉 This aggressive timeline shows that the company views these Phase 3 results as highly supportive, suggesting they are ready to move rapidly to the regulatory stage.

🧬 Other Programs in Development 🧬

Monopar is not only focused on Wilson disease. The company has several other programs in development, showing a broader commitment to fighting genetic and cancer-related diseases.

👉 Cancer Programs: They have radiopharmaceutical programs targeting advanced cancers. These include:

• MNPR-101-Zr: Currently in Phase 1 (for imaging advanced cancers).
• MNPR-101-Lu and MNPR-101-Ac225: Both in the Phase 1a stage and late preclinical stage, respectively, for the treatment of advanced cancers.

🤝 Investor Relations and Contact Details 📧

For investors and partners interested in the company's financial or scientific progress, the filing provides specific contact channels.

👉 Key contact details include:

• Investor Relations Contact: Quan Vu, Chief Financial Officer
• Email: [email protected]
• Website: www.monopartx.com
• Social Media: X: @MonoparTx | LinkedIn: Monopar Therapeutics

🧠 The Analogy ⚙️

Think of Wilson disease as a leaky faucet (copper) constantly causing damage inside your house (the brain). Standard treatments are like temporary band-aids—they slow the leak but don't stop the damage completely. ALXN1840, however, acts like a specialized, industrial-grade valve: it not only detects and seals the leaks and actively removes the excess materials, providing sustained, structural repair over time.

🧩 Final Takeaway 💡

Monopar's Phase 3 data provides highly encouraging evidence that ALXN1840 is a potentially transformative treatment for neurologic Wilson disease. The company is leveraging these strong metrics to set a clear path toward an FDA New Drug Application submission in mid-2026.